Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

New approach methodologies: drug screening platform to identify antifibrotic compounds.

This high-throughput screening system uses human reporter induced pluripotent stem cell-derived cardiac fibroblasts to identify initial hits with potential antifibrotic effects, followed by counter-screening using iPS cell-derived cardiomyocytes to exclude compounds with potential cardiotoxicity.

Hao Zhang, Lu Ren, Rihua Huang et al. · 0 citations
Aug 2026

RUNX1-driven endothelial-to-mesenchymal transition contributes to remodelling in LMNA cardiomyopathy.

RUNX1-driven EndoMT represents a central mechanism linking LMNA mutations to fibrotic remodelling in LMNA cardiomyopathy and supports endothelial transcriptional reprogramming and RUNX1 signalling as potential therapeutic targets in fibrotic cardiomyopathy.

David Wu, D. Tripathi, Amit Manhas et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.